New Antibiotic Class Is Aim Of Evotec R&D Pact With Nosopharm
Executive Summary
Evotec and Nosopharm plan to develop and then test in humans the first novel antibiotic class for fighting Gram-negative Enterobacteriaceae infections in 40 years
| Table |
|---|
Advertisement
Topics
- Subjects
- Deals
- Platform Technologies
- StartUps and SMEs
- Companies
- Research & Development
- Therapy Areas
- Infectious Diseases
- Industries
- BioPharmaceutical
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SC125519
Ask The Analyst
Please Note: Click here for more information on the Ask the Analyst service.
Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.
All fields are required.
SC125519
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.